PCM
MCRB icon

Penserra Capital Management’s Seres Therapeutics MCRB Stock Holding History

Penserra Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-105
Closed -$14K – 1469
2021
Q3 		$14K Buy
105
+1
+1% +$196 ﹤0.01% 1301
2021
Q2 		$49K Buy
104
+1
+1% +$422 ﹤0.01% 1005
2021
Q1 		$42K Sell
103
-2
-2% -$921 ﹤0.01% 841
2020
Q4 		$51K Buy
105
+67
+176% +$39.2K ﹤0.01% 682
2020
Q3 		$21K Buy
+38
New +$12.6K ﹤0.01% 733

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Penserra Capital Management's MCRB Position: Q4 2021 in Review

Penserra Capital Management sold out of Seres Therapeutics (MCRB) in Q4 2021, closing a stake of 105 shares — an estimated $14K sold.

Penserra Capital Management first reported a position in MCRB in Q3 2020 and held it in 5 quarters. The position peaked at $51K in Q4 2020. 148 funds tracked by Wall St. Rank hold MCRB as of Q4 2021.

  • Penserra Capital Management reported no remaining Seres Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 105 Seres Therapeutics shares in Q4 2021, an estimated $14K.
  • Penserra Capital Management first reported a position in Seres Therapeutics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Seres Therapeutics position peaked at $51K in Q4 2020.
  • 148 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.